Laser Treatment for Psoriasis | Excimer Laser Therapy at MyMedicPlus — Cost, Top Hospitals & Success Rates | MyMedicPlus

Laser treatment for psoriasis, most commonly delivered via the 308 nm excimer laser, represents a major advance in targeted phototherapy for localised chronic plaque psoriasis. Unlike conventional broadband UVB or narrowband UVB (NB-UVB) phototherapy — which irradiates the entire body surface, including uninvolved skin — the excimer laser delivers a high-intensity, precisely focused beam of 308 nm UVB light exclusively to psoriatic plaques, sparing surrounding healthy tissue from unnecessary UV exposure.

Psoriasis is a T-lymphocyte-driven immune-mediated skin disease characterised by hyperproliferation of keratinocytes and dysregulated cytokine signalling (IL-17, IL-23, TNF-alpha pathways). UVB phototherapy at 308 nm exerts its therapeutic effect through several overlapping mechanisms:

• Induction of T-cell apoptosis within psoriatic plaques (reducing the pathogenic T-cell infiltrate)
• Suppression of inflammatory cytokine production (particularly IL-17 and IFN-gamma)
• Inhibition of keratinocyte hyperproliferation by UV-induced DNA damage to basal keratinocytes
• Formation of immunosuppressive photoproducts including urocanic acid isomers

The excimer laser achieves these effects at fluences far higher than conventional NB-UVB phototherapy (up to 3–6 MED per session versus 0.5–1.0 MED for NB-UVB), enabling faster clearance in fewer sessions while limiting exposure to uninvolved skin. Clinical studies report PASI-75 (75% improvement in Psoriasis Area and Severity Index) in 57–72% of patients completing a full treatment course of 20–30 sessions, with remission durations of 3–6 months or longer in many responders.

While psoriasis is the primary indication, the 308 nm excimer laser and other targeted phototherapy systems have demonstrated clinical benefit across several other inflammatory and pigmentary skin conditions.

• Chronic Plaque Psoriasis (Psoriasis Vulgaris): The core indication. Particularly effective for localised, recalcitrant plaques involving <10% body surface area (BSA) — the typical threshold below which systemic biologics are not yet indicated. Plaques on elbows, knees, scalp, and lower legs respond well. Palmoplantar psoriasis shows variable response.
• Scalp Psoriasis: A targeted 308 nm excimer handpiece allows precise treatment through the hair-bearing scalp without requiring total-body phototherapy. This addresses a historically difficult-to-treat subtype where topical access is limited by hair.
• Nail Psoriasis: Some centres use excimer laser targeted at the proximal nail fold and nail matrix to improve nail pitting, onycholysis, and subungual hyperkeratosis, though evidence is limited and response rates are lower than for plaque disease.
• Vitiligo: The 308 nm excimer laser stimulates melanocyte migration and proliferation in depigmented patches (see separate MyMedicPlus article on Laser Treatment for Vitiligo).
• Atopic Dermatitis (Eczema): Localised, recalcitrant patches of atopic dermatitis may respond to targeted excimer laser phototherapy, particularly in adults with lichenified plaques. Supported by multiple small RCTs.
• Alopecia Areata: Targeted UVB via excimer laser has shown hair regrowth benefit in some patients with patchy alopecia areata, with a proposed mechanism of local immunomodulation.
• Mycosis Fungoides (Early Stage CTCL): Patch and thin plaque stage cutaneous T-cell lymphoma may be treated with targeted UVB phototherapy for localised disease.

The excimer laser is most appropriate for a specific subset of psoriasis patients. Careful patient selection maximises benefit and avoids unnecessary treatment in those unlikely to respond.

• Optimal Candidates: Adults with chronic plaque psoriasis affecting <10% BSA; patients with localised, treatment-resistant plaques despite adequate trials of topical corticosteroids, vitamin D analogues, and/or topical calcineurin inhibitors; patients in whom systemic therapy is not yet indicated or has been refused.
• Body Surface Area: Excimer laser is a targeted device and is impractical for widespread psoriasis (>10–15% BSA). Patients with extensive disease are better served by conventional NB-UVB phototherapy or systemic agents (methotrexate, ciclosporin, biologics).
• Phototype Considerations: All Fitzpatrick skin types (I–VI) are eligible, with starting fluence calibrated to the patient's minimal erythema dose (MED). Darker skin types tolerate higher doses per session but responses are comparable across phototypes.
• Contraindications:

• Personal or family history of melanoma or multiple non-melanoma skin cancers (relative contraindication; risk-benefit discussion essential)
• Lupus erythematosus or other photosensitive dermatoses
• Use of photosensitising medications (psoralens, tetracyclines, quinolones, amiodarone) without explicit protocol adjustment
• Active skin infection in the treatment area
• Xeroderma pigmentosum or other DNA repair disorders
• Active or recent immunosuppression incompatible with UV exposure (case-by-case evaluation)

Pregnant patients are generally advised against phototherapy initiation due to the theoretical risk of folate photodegradation, though risks are low. Patients with a history of PUVA therapy exceeding 200 sessions carry a higher baseline risk of cutaneous malignancy and require careful monitoring.

Several phototherapy modalities are available for psoriasis, with the excimer laser sitting within a broader spectrum of UVB and UVA-based approaches. The choice depends on disease extent, plaque location, patient history, and available technology.

• 308 nm Excimer Laser (XTRAC, MEL 83): Targeted delivery of high-dose UVB to psoriatic plaques only. Starting dose typically 2–3 x MED of uninvolved skin; doses escalated by 25% per session in absence of significant erythema. Standard course: 20–30 sessions delivered 2–3 times per week over 8–12 weeks. Produces higher fluence per session than NB-UVB, enabling faster clearance.
• 308 nm Excimer Light (Non-laser Monochromatic Excimer Light): Similar wavelength to the laser but delivered via a fluorescent excimer lamp rather than a true laser. Less coherent beam; effective for larger plaques. Slightly lower per-session fluence achievable than true excimer laser but broader coverage per pass.
• Narrowband UVB (NB-UVB, 311 nm): The most widely available and evidence-based whole-body phototherapy modality. Delivered in a phototherapy cabinet; irradiates the entire skin surface. Preferred for widespread psoriasis (>10% BSA). Typically 3 sessions per week for 8–12 weeks. PASI-75 achieved in approximately 60–65% at 12 weeks. Cannot spare uninvolved skin.
• Broadband UVB (BB-UVB): Largely superseded by NB-UVB due to inferior efficacy and greater erythemogenic risk. Still used in some resource-limited settings.
• PUVA (Psoralen + UVA): Oral or topical psoralen photosensitiser followed by UVA irradiation. Highly effective (PASI-75 in 75–80% at 15–20 sessions) but associated with significant long-term photocarcinogenesis risk, particularly squamous cell carcinoma. Reserved for severe, NB-UVB-resistant disease. Largely replaced by biologics in high-income settings.
• Combination Protocols: Excimer laser combined with topical calcipotriol (vitamin D3 analogue) demonstrates synergistic benefit — calcipotriol reduces plaque thickness and scale, enhancing UV penetration into the dermis while independently suppressing T-cell activation. Applied twice daily between laser sessions, calcipotriol combination has been shown to reduce the number of sessions required for clearance by 30–40% compared to laser monotherapy.

The 308 nm excimer laser offers several advantages over conventional phototherapy and topical-only management for patients with localised plaque psoriasis.

• Targeted Delivery: Treatment is confined to psoriatic plaques only. Surrounding uninvolved skin receives zero UV exposure, eliminating the cumulative photocarcinogenesis risk that accompanies whole-body NB-UVB or PUVA therapy over years of use.
• High Clearance Rates: Multiple controlled studies demonstrate PASI-75 in 57–72% of patients after a standard 20–30 session course, with some trials reporting complete clearance (PASI-100) in 20–25% of responders.
• Faster Clearance: The high-intensity beam (up to 3,000 mJ/cm² per session for resistant plaques versus <500 mJ/cm² for NB-UVB) achieves plaque clearance more rapidly than conventional phototherapy, with many patients seeing significant improvement within 10–12 sessions.
• Improved Quality of Life (DLQI): Studies consistently demonstrate significant improvements in Dermatology Life Quality Index (DLQI) scores following excimer laser treatment, with reductions of 5–10 points from baseline in clinical trials, reflecting meaningful improvements in daily activities, social functioning, and psychological well-being.
• Durable Remission: Responders typically maintain clearance for 3–6 months after completing the treatment course. Patients who achieved complete clearance tend to have longer remissions than partial responders.
• Reduced Topical Steroid Exposure: Successful excimer laser clearance reduces reliance on potent topical corticosteroids, minimising risks of skin atrophy, telangiectasia, and systemic absorption associated with long-term steroid use on plaques.
• No Systemic Immunosuppression: Unlike methotrexate, ciclosporin, or biological agents, excimer laser therapy does not involve systemic immunosuppression, making it safe for patients with comorbidities (infections, malignancy history) where systemic agents are contraindicated.

The excimer laser has a well-established safety profile developed over two decades of clinical use. Adverse effects are predominantly localised and dose-dependent.

• Erythema: Mild to moderate redness in treated areas is expected and indicates adequate dosing. Significant erythema (sunburn-like reaction) indicates over-treatment; doses are reduced by 25% at the subsequent session. Severe blistering erythema is a treatment error and should not occur with proper MED-based dosing.
• Hyperpigmentation: Transient darkening of treated plaques and surrounding skin, particularly in Fitzpatrick III–VI. Resolves over weeks to months following treatment completion. Generally more cosmetically acceptable than the psoriatic plaque itself.
• Hypopigmentation: Post-inflammatory hypopigmentation within cleared plaques is common and expected, as UV therapy can affect local melanocyte density. Usually resolves spontaneously but may persist for months in some patients.
• Skin Atrophy / Freckling: With prolonged courses (>100 sessions over multiple years), cumulative UV effects may produce mild chronic photodamage signs including fine freckling or textural changes in treated sites. Risk is substantially lower than equivalent-duration whole-body phototherapy.
• Theoretical Carcinogenesis Risk: The targeted nature of excimer laser virtually eliminates the whole-body cumulative UV dose that drives photocarcinogenesis with conventional phototherapy. No excess skin cancer risk attributable specifically to excimer laser has been documented in the published literature, though long-term (20+ year) data are limited.
• Koebner Phenomenon: Psoriasis can koebnerise (new plaques develop) at sites of skin trauma. Excessive laser-induced erythema in perilesional skin could theoretically trigger Koebner response; proper dose management minimises this risk.

Ongoing management between and after excimer laser sessions is critical to maximising and sustaining treatment outcomes.

• Inter-session Skincare: Apply an emollient (aqueous cream, petroleum jelly, or urea-based moisturiser) to treated plaques daily. Adequate hydration reduces scale and may improve UV penetration at subsequent sessions. Avoid exfoliating agents or keratolytics in the 24 hours before each session to prevent over-sensitisation of the skin to UV.
• Topical Calcipotriol Protocol: Apply calcipotriol 50 mcg/g ointment to active plaques twice daily on non-treatment days. On treatment days, apply calcipotriol after — not before — the laser session to avoid photodegradation of the calcipotriol molecule by UV light.
• Session Frequency: 2–3 sessions per week is the evidence-based standard protocol. Shorter inter-session intervals (daily treatment) do not improve outcomes and increase erythema risk; longer intervals (>5 days) reduce treatment intensity and may require additional sessions for equivalent clearance.
• Maintenance After Clearance: Upon achieving plaque clearance, many clinicians recommend a tapering maintenance schedule (weekly for 4 weeks, then monthly) to prolong remission. Patients who relapse receive a 'booster' course of 10–15 sessions.
• DLQI and PASI Monitoring: Standardised PASI and DLQI scoring at baseline, mid-course (session 12–15), and end of course enables objective assessment of treatment response and documentation for insurance and reimbursement purposes.
• Sun Protection: Advise patients that treated skin — particularly hypopigmented post-plaque areas — is more susceptible to sunburn. Broad-spectrum SPF 30+ sunscreen should be applied to cleared plaques on sun-exposed areas.
• Systemic Therapy Escalation: Patients who fail to achieve PASI-50 after 20–25 sessions of excimer laser should be referred for evaluation of systemic therapy (methotrexate, apremilast, or IL-17/IL-23 biologic agents).

The cost of excimer laser phototherapy for psoriasis varies significantly based on healthcare system, treatment setting, and geographic location.

• Number of Sessions: A standard course of 20–30 sessions represents the primary cost driver. Patients who require additional sessions (30–40 for resistant plaques) face proportionally higher total costs.
• Session Frequency: Twice-weekly versus three-times-weekly protocols do not differ greatly in per-session cost but affect the total duration and therefore indirect costs (travel, time off work).
• Treatment Setting: Hospital-based phototherapy units often bill differently from private dermatology clinics. In countries with public dermatology services, phototherapy may be substantially subsidised or provided free at point of care.
• Insurance Coverage: In the USA, excimer laser therapy is covered by most major insurance plans for chronic plaque psoriasis that has failed topical monotherapy, subject to prior authorisation. Coverage criteria typically require documented failure of topical corticosteroids and/or vitamin D analogues.
• Geographic Cost Ranges (per session):

• USA (private pay): USD 150–400 per session (USD 3,000–12,000 for a full course)
• UK (NHS): Usually provided at no direct cost when referred by a dermatologist
• India / Thailand / Turkey: USD 20–60 per session (USD 500–1,800 for a full course)
• Singapore / UAE: USD 80–180 per session

Patients travelling for medical treatment often achieve significant savings on multi-session phototherapy courses at internationally accredited dermatology centres in India, Thailand, or Turkey, where the cost of a complete 30-session course may be equivalent to just 5–8 sessions in the USA.

Excimer laser phototherapy sits within a broad therapeutic landscape for psoriasis. The optimal treatment approach depends on disease severity, body surface area affected, comorbidities, and patient preference.

• Topical Therapies (Mild–Moderate Localised Disease): Topical corticosteroids (betamethasone dipropionate, clobetasol propionate), vitamin D analogues (calcipotriol, calcipotriol/betamethasone combination), coal tar preparations, and topical retinoids (tazarotene) remain the first-line approach for limited plaque psoriasis. Effective for mild disease; often insufficient for thick, recalcitrant plaques.
• Narrowband UVB Phototherapy (NB-UVB): The preferred whole-body phototherapy for moderate-to-severe psoriasis (>10% BSA). Well-established evidence base, widely available, and safe for long-term use. Preferred over excimer laser for widespread disease due to treatment efficiency.
• PUVA (Psoralen + UVA): Highly effective for severe disease but associated with long-term photocarcinogenesis risk. Reserved for NB-UVB-refractory disease where biologics are contraindicated.
• Conventional Systemic Agents: Methotrexate (15–25 mg weekly), ciclosporin (3–5 mg/kg/day), acitretin (25–50 mg/day), and apremilast (30 mg twice daily) provide systemic disease control for moderate-to-severe psoriasis but require monitoring for organ toxicity.
• Biological Agents (Biologics): TNF-alpha inhibitors (adalimumab, etanercept), IL-17 inhibitors (secukinumab, ixekizumab, bimekizumab), and IL-23 inhibitors (risankizumab, guselkumab) represent the most effective available therapies for moderate-to-severe psoriasis, with PASI-90 and PASI-100 rates of 50–80% in clinical trials. Appropriate for >10% BSA or significant impact on quality of life despite conventional therapy.
• Topical Roflumilast (PDE4 Inhibitor): A newer steroid-free topical agent approved for plaque psoriasis; an effective alternative for patients who wish to avoid long-term topical steroid use.